Alliqua to Present at Biotech Showcase 2013 on January 7, 2013

        Alliqua to Present at Biotech Showcase 2013 on January 7, 2013

PR Newswire

NEW YORK, Jan. 7, 2013

NEW YORK, Jan.7, 2013 /PRNewswire/ --Alliqua, Inc. (OTCQB:ALQA) ("Alliqua"
or the "Company") today announced that James Sapirstein, President and CEO, of
Alliqua will present an overview of the Company's business and recent
developments at Biotech Showcase 2013, held January 7-9, 2013, at the Parc 55
Wyndham Union Square Hotel in San Francisco, California.

Mr. Sapirstein's presentation of Alliqua will take place at 4:45 PM (PST) on
January 7, 2013 in the Powell Room (Track D). Mr. Sapirstein will also be
available to participate in one-on-one meetings with registered attendees for
the duration of the conference.

About Biotech Showcase 2103 
Co-produced by Demy-Colton Life Science Advisors and EBD Group, Biotech
Showcase is an investor and partnering conference devoted to providing private
and public biotechnology and life sciences companies an opportunity to present
to, and meet with, investors and pharmaceutical executives during the course
of one of the industry's largest annual healthcare investor conferences. Now
in its fifth year, Biotech Showcase is expected to attract upwards of 1,500
attendees.

About Alliqua, Inc.
Alliqua, Inc. (ALQA) ("Alliqua") is a biopharmaceutical company focused on the
development, manufacturing, and distribution of proprietary transdermal wound
care and drug delivery technologies. Alliqua's leading technology platform
produces hydrogels, a 3-dimensional cross-linked network of water soluble
polymers capable of numerous chemical configurations.

Alliqua currently markets its new line of 510K FDA-approved hydrogel products
for wound care under the SilverSeal^® brand. Alliqua's electron beam
production process, located at its 16,000 square foot GMP manufacturing
facility in Langhorne PA, allows Alliqua to aggressively develop and custom
manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized
for various transdermal applications to address market opportunities in the
treatment of wounds as well as the delivery of numerous drugs or other agents
for pharmaceutical and cosmetic industries. Additionally, Alliqua's drug
delivery platform, in combination with certain active pharmaceutical
ingredients, can provide pharmaceutical companies with a transdermal
technology to enhance patient compliance and potentially extend the patent
life of valuable drug franchises. Additionally, our subsidiary, HepaLife
Biosystems, Inc., focuses on the development of a cell-based bioartificial
liver system, known as HepaMate™.

For additional information, please visit www.alliqua.com. To receive future
press releases via email, please visit: http://alliqua.com/contacts.

Any statements contained in this press release regarding our ongoing research
and development and the results attained by us to-date have not been evaluated
by the Food and Drug Administration.

Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements
are generally identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend," or "project"
or the negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue reliance on
these forward-looking statements, as these statements are subject to numerous
factors and uncertainties outside of the our control that can make such
statements untrue, including, but not limited to, inadequate capital, adverse
economic conditions, intense competition, lack of meaningful research results,
entry of new competitors and products, adverse federal, state and local
government regulation, termination of contracts or agreements, technological
obsolescence of our products, technical problems with our research and
products, price increases for supplies and components, inability to carry out
research, development and commercialization plans, loss or retirement of key
executives and research scientists and other specific risks. We currently have
no commercial products intended to diagnose, treat, prevent or cure any
disease. The statements contained in this press release regarding our ongoing
research and development and the results attained by us to-date have not been
evaluated by the Food and Drug Administration. There can be no assurance that
further research and development, and/or whether clinical trial results, if
any, will validate and support the results of our preliminary research and
studies. Further, there can be no assurance that the necessary regulatory
approvals will be obtained or that we will be able to develop new products on
the basis of our technologies. In addition, other factors that could cause
actual results to differ materially are discussed in our Annual Report on Form
10-K filed with the SEC on March 29, 2012 and our most recent Form 10-Q
filings with the SEC. Investors and security holders are urged to read these
documents free of charge on the SEC's web site at www.sec.gov. We undertake no
obligation to publicly update or revise our forward- looking statements as a
result of new information, future events or otherwise.

Contacts for Alliqua, Inc.
Steven Berger
Chief Financial Officer
646-218-1450
info@alliqua.com

SOURCE Alliqua, Inc.

Website: http://www.alliqua.com
 
Press spacebar to pause and continue. Press esc to stop.